Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 19/20 | 0.61 |
| ▸ | ABL1 | P00519 | 10/20 | 0.61 |
| ▸ | EGFR | P00533 | 3/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.61 |
| ▸ | FYN | P06241 | 3/20 | 0.61 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | LCK | P06239 | 2/20 | 0.61 |
| ▸ | YES1 | P07947 | 2/20 | 0.61 |
| ▸ | LYN | P07948 | 2/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.61 |
| ▸ | PRKACA | P17612 | 2/20 | 0.61 |
| ▸ | FRK | P42685 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.61 |
| ▸ | BLK | P51451 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409549 | 0.84 | SRC (0.47) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL15471369 | 0.83 | SRC (0.58) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL13019650 | 0.83 | SRC (0.64) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL14617301 | 0.81 | SRC (0.89) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL23055859 | 0.80 | SRC (0.58) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL3782929 | 0.80 | SRC (0.58) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL22521563 | 0.80 | KDM4E (0.63) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL2961144 | 0.80 | SRC (0.58) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL13019664 | 0.79 | SRC (0.57) | SRCABL1EGFRKDRRIPK2 | |
| SCHEMBL1962682 | 0.78 | SRC (0.78) | SRCABL1EGFRKDRRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-9840509-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2017-12-12 | — | — | US | disclosed |
| US-9840509-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2017-12-12 | — | — | US | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9446130-B2 | BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446130-B2 | BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150353565-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353565-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | BTK, LYN, SYK | SRC 38/4885ABL1 5/4885EGFR 804/4885 |
| US-20150353565-A1 | BTK INHIBITORS | BTK, SYK, LYN | SRC 10/4885ABL1 4/4885EGFR 495/4885 |
| US-20170008899-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | SRC 22/4885ABL1 3/4885EGFR 425/4885 |
| US-20140221333-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | SRC 20/4885ABL1 3/4885EGFR 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.